Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

Abstract

Treatment-related mortality after reduced-intensity conditioning followed by allogeneic HSCT was low. The procedure induced molecular remissions in patients with advanced CLL. The observation of late remissions provided evidence of a graft-versus-leukemia effect.

Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation

“…Patients after alloSCT are generally at a higher risk of infection due to poor immune reconstitution. 25,26 Previous reports did not observe an increased incidence of severe infections in immunocompromised patients on ibrutinib compared with chemo-immunotherapy. 4,5 Nevertheless, the adverse events in patients on ibrutinib following allogeneic transplantation may be different.…”

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

“…DLI is already approved as an effective strategy for other lymphoid malignancies in relapse after allo-SCT, such as low-grade B-cell lymphoproliferation. 20,21 In contrast, because of more rapid relapse, an immune strategy based on DLI is less effective in more aggressive diseases such as acute leukemia and large B-cell NHL. In the largest series of patients treated with DLI for cutaneous T-cell lymphoma, preceded by chemotherapy or radiotherapy for 5 of 12 patients, a response was observed in 8 patients.…”

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

“…The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation Marie Thérèse Rubio, 1,2,3 Myriam Labopin, 1,4 Didier Blaise, 5 Gerard Socié, 6 Rafael Rojas Contreras, 7 Patrice Chevallier, 8 Miguel A. Sanz, 9 Stéphane Vigouroux, 10 Anne Huynh, 11 Avichai Shimoni, 12 Claude-Eric Bulabois, 13 Nerea Caminos, 14 Lucía López-Corral, 15 Arnon Nagler, 12,4 * and Mohamad Mohty 1,2,3,4 * been poorly explored. While, the combination of CsA and a short course of methotrexate (MTX) after transplantation is considered as the gold standard for GVHD prophylaxis after conventional myeloablative allogeneic HSCT from HLA-identical siblings, 15,16 there is no consensus on the optimal preventive regimen for GVHD prophylaxis after RIC allogeneic HSCT.…”

“…[1][2][3][4] In this setting, the combination of fludarabine and 2 days of busulfan (Flu-Bu2) is a widely used RIC regimen. [1][2][3]5 Initially described in HLA identical sibling peripheral blood stem cell transplantation, Flu-Bu2 was combined with anti-T-lymphocyte globulin (ATG) (Fresenius 10 mg/kg/day) and cyclosporine A (CsA) alone for the prophylaxis of graft-versus-host-disease (GVHD). 1 However, the best GVHD prophylaxis combination in the Flu-Bu2 RIC regimen has not yet been established.…”